Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials

INTRODUCTION: Somapacitan is a long-acting growth hormone (GH) derivative being developed for once-weekly dosing in patients with GH deficiency (GHD). Our objective was to evaluate the impact of kidney or hepatic impairment on somapacitan exposure in adults. METHODS: In two open-label, parallel-grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentz Damholt, Birgitte, Dombernowsky, Sarah Louise, Dahl Bendtsen, Mette, Bisgaard, Charlotte, Højby Rasmussen, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332591/
https://www.ncbi.nlm.nih.gov/pubmed/33754315
http://dx.doi.org/10.1007/s40262-021-00990-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332591/
https://www.ncbi.nlm.nih.gov/pubmed/33754315
http://dx.doi.org/10.1007/s40262-021-00990-7

Ejemplares similares